Patents by Inventor Eva Szabo
Eva Szabo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230000177Abstract: The present invention relates to a disposable clothing cover that has an integrated napkin. The cover provides the functionality of a bib and a napkin and prohibits clothes from inadvertently becoming stained. The cover has cloth friendly adhesive lines which are used for removably attaching the cover to clothing of a wearer. A perforated curved portion positioned below the neck of a wearer of the cover is configured to be detached and functions like a napkin while the remaining part of the cover functions as a bib. The cover has a pair of adhesive tabs that can be used for securing a folded bottom edge of the cover enabling the creation of a pocket at the bottom of the cover to catch food items dropped during eating and drinking. The clothing cover can be packaged individually, formed in a roll, or stacked in a dispenser box.Type: ApplicationFiled: July 5, 2022Publication date: January 5, 2023Inventors: Marilyn Weaver, Eva Szabo, Karen Barnette
-
Publication number: 20200087269Abstract: The present invention relates a new process for the preparation of ozanimod of the formula and acid addition salts, via new intermediates and a new polimop form of ozanimod base.Type: ApplicationFiled: May 18, 2018Publication date: March 19, 2020Applicant: EGIS GYOGYSZERGYAR ZRT.Inventors: Marta PORCS-MAKKAY, Gyula SIMIG, Eniko MOLNAR, Janos PETHO, Balazs VOLK, Laszlo SZLAVIK, Eva SZABO, Judit HALASZ
-
Patent number: 9822086Abstract: The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an economical process for the preparation of the compound having the international non-proprietary name (INN) vortioxetine and the chemical nomenclature 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. Vortioxetine corresponds to the following Formula Still more particularly the invention relates to the preparation of high purity vortioxetine L-(+)-mandelate salt of the Formula IX, the conversion of this salt into other highly pure salts and also to the formulation of said salts.Type: GrantFiled: January 30, 2015Date of Patent: November 21, 2017Assignee: EGIS GYOGYSZERGYAR ZRT.Inventors: Istvan Ling, Gyorgy Jeges, Gyorgyi Kovanyine Lax, Balazs Volk, Peter Gregor, Jeno Peter Seres, Andras Dancso, Zoltan Varga, Eva Szabo
-
Publication number: 20170114034Abstract: The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an economical process for the preparation of the compound having the international non-proprietary name (INN) vortioxetine and the chemical nomenclature 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. Vortioxetine corresponds to the following Formula Still more particularly the invention relates to the preparation of high purity vortioxetine L-(+)-mandelate salt of the Formula IX, the conversion of this salt into other highly pure salts and also to the formulation of said salts.Type: ApplicationFiled: January 30, 2015Publication date: April 27, 2017Applicant: Egis Gyogyszergyar Zrt.Inventors: Istvan LING, Gyorgy JEGES, Gyorgyi KOVANYINE LAX, Balazs VOLK, Peter GREGOR, Jeno Peter SERES, Andras DANCSO, Zoltan VARGA, Eva SZABO
-
Publication number: 20160264935Abstract: The present disclosure provides transformed human pluripotent stem cell (t-hPSC). t-hPSCs are not dependent on Oct4 for renewal and survival, however exhibit a sensitivity to reduced levels of the transcription factor Nanog. Also provided are methods of culturing cells for use in a cell-based screening assay comprising placing one or more transformed human pluripotent stem cells into a receptacle and culturing said stem cells in the receptacle to form a monolayer of stem cells without cell overlap. Methods of screening compounds using t-hPSCs are also described.Type: ApplicationFiled: May 25, 2016Publication date: September 15, 2016Inventors: Mickie Bhatia, Tamra Werbowetski-Ogilvie, Eleftherios Sachlos, Daniela Fischer Russell, Sarah Laronde, JungBok Lee, Eva Szabo, Ruth Risueno
-
Patent number: 9365821Abstract: The present disclosure provides transformed human pluripotent stem cell (t-hPSC). t-hPSCs are not dependent on Oct4 for renewal and survival, however exhibit a sensitivity to reduced levels of the transcription factor Nanog. Also provided are methods of culturing cells for use in a cell-based screening assay comprising placing one or more transformed human pluripotent stem cells into a receptacle and culturing said stem cells in the receptacle to form a monolayer of stem cells without cell overlap. Methods of screening compounds using t-hPSCs are also described.Type: GrantFiled: July 11, 2014Date of Patent: June 14, 2016Assignee: MCMASTER UNIVERSITYInventors: Mickie Bhatia, Tamra Werbowetski-Ogilvie, Eleftherios Sachlos, Daniela Fischer Russell, Sarah Laronde, JungBok Lee, Eva Szabo, Ruth Risueno
-
Patent number: 9340772Abstract: The present disclosure provides a method of generating progenitor cells, such as hematopoietic or neural progenitor cells, from fibroblasts, such as dermal fibroblasts, comprising providing fibroblasts that express or are treated with a POU domain containing gene or protein and culturing the cells under conditions that allow production of progenitor cells, without traversing the pluripotent state. Also provided is a method of isolating a subpopulation of fibroblasts with reprogramming potential comprising providing fibroblasts that express an Oct-4-reporter and isolating cells that are positive for the reporter. Further provided is a method of generating reprogrammed fibroblast-derived induced pluripotent stem cells. Also provided are uses and assays of the cells produced by the methods of the disclosure.Type: GrantFiled: October 29, 2010Date of Patent: May 17, 2016Assignee: McMaster UniversityInventors: Mickie Bhatia, Eva Szabo, Shravanti Rampalli-Deshpande, Ruth Munoz Risueno
-
Publication number: 20150038371Abstract: The present disclosure provides transformed human pluripotent stem cell (t-hPSC). t-hPSCs are not dependent on Oct4 for renewal and survival, however exhibit a sensitivity to reduced levels of the transcription factor Nanog. Also provided are methods of culturing cells for use in a cell-based screening assay comprising placing one or more transformed human pluripotent stem cells into a receptacle and culturing said stem cells in the receptacle to form a monolayer of stem cells without cell overlap. Methods of screening compounds using t-hPSCs are also described.Type: ApplicationFiled: July 11, 2014Publication date: February 5, 2015Inventors: Mickie Bhatia, Tamra Werbowetski-Ogilvie, Eleftherios Sachlos, Daniela Fischer Russell, Sarah Laronde, JungBok Lee, Eva Szabo, Ruth Risueno
-
Publication number: 20120252697Abstract: The present disclosure provides transformed human pluripotent stem cell (t-hPSC). t-hPSCs are not dependent on Oct4 for renewal and survival, however exhibit a sensitivity to reduced levels of the transcription factor Nanog. Also provided are methods of culturing cells for use in a cell-based screening assay comprising placing one or more transformed human pluripotent stem cells into a receptacle and culturing said stem cells in the receptacle to form a monolayer of stem cells without cell overlap. Methods of screening compounds using t-hPSCs are also described.Type: ApplicationFiled: September 1, 2010Publication date: October 4, 2012Applicant: Mcmaster UniversityInventors: Mickie Bhatia, Tamra Werbowetski-Ogilvie, Eleftherios Sachlos, Daniela Fischer Russell, Sarah Laronde, JungBok Lee, Eva Szabo, Ruth M. Risueno
-
Publication number: 20120214236Abstract: The present disclosure provides a method of generating progenitor cells, such as hematopoietic or neural progenitor cells, from fibroblasts, such as dermal fibroblasts, comprising providing fibroblasts that express or are treated with a POU domain containing gene or protein and culturing the cells under conditions that allow production of progenitor cells, without traversing the pluripotent state. Also provided is a method of isolating a subpopulation of fibroblasts with reprogramming potential comprising providing fibroblasts that express an Oct-4-reporter and isolating cells that are positive for the reporter. Further provided is a method of generating reprogrammed fibroblast-derived induced pluripotent stem cells. Also provided are uses and assays of the cells produced by the methods of the disclosure.Type: ApplicationFiled: October 29, 2010Publication date: August 23, 2012Applicant: MCMASTER UNIVERSITYInventors: Mickie Bhatia, Eva Szabo, Shravanti Rampalli-Deshpande, Ruth Munoz Risueno, Kausalia Vijayaragavan
-
Patent number: 5518722Abstract: A skin regenerating composition which comprises as active ingredients a mixture of skin regeneratingly effective amounts each of an extract of the plants chickweed and pansy.Type: GrantFiled: March 28, 1994Date of Patent: May 21, 1996Assignee: Biogal Gyogyszergyar RtInventors: Erzebet Szaloki, Eva Szabo, Eva Hegedus, Erika Jacso, Iren Hangacsi, Kalman Kerek, Erzsebet Bereczki, Erzsebet Sas, Tunde Szabo, Erika Karancsi, Agnes Fabian, Zsolt gni, Gabriella Papp, Aniko Kovacs, Ilona Nagy, Tunde Jakab, Gabriella Demko, Erika Apagyi
-
Patent number: 5468492Abstract: A topical cosmetic composition of an extract of a hair fallout reducing effective amount of Gingko biloba (maidenhair tree) leaves, and an extract of the root of Liquiritia officinalis (sweet-root), and one or more cosmetically acceptable solid or liquid carrier, and optionally one or more cosmetically acceptable supplementary ingredient.Type: GrantFiled: December 27, 1993Date of Patent: November 21, 1995Assignee: Biogal Gyogyszergyar RTInventors: Erzsebet Szaloki, Ilona Kristof, Veronika Pal, Eva Szabo
-
Patent number: 5391737Abstract: This invention relates to a new and improved process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]-quinazolin-2[3H]-one of formula ##STR1## (anagrelide), a valuable blood platelet antiaggregative compound. According to the process of the invention the compound of formula (I) is prepared by subjecting a new 2-cyanoiminoquinazoline derivative of the general formula ##STR2## wherein R stands for cyano or a group of the formula COOR.sup.1, in the latter R.sup.1 representing lower alkyl optionally carrying a phenyl substituent, to thermal cyclization in an acidic medium.The invention also relates to new 2-cyanoiminoquinazo-lines of the general formula (III) used for the production of anagrelide and to the preparation of the said compounds.The invention provides an advantageous process for the preparation of anagrelide which is devoid of the drawbacks of the hitherto known processes and renders possible the production of the compound of the formula (I) on industrial scale, too.Type: GrantFiled: November 24, 1993Date of Patent: February 21, 1995Assignee: EGIS GyogyszergyarInventors: Jozsef Reiter, Peter Trinka, Peter Tompe, Eva Szabo, Peter Slegel, Janos Brlik, Agnes Halbauer nee Nagy, Ilona Sztruhar, Magdolna Kenyeres nee Feher, Frigyes Gorgenyi, Margit Csorgo, Szvetlana Zsarnoczai nee Kurnyecova, Sarolta Benko nee Markus, Gabor Gigler, Dezso Danyi, Pal Fekete, Maria Kiraly nee Ignacz